Without comment on the broader subject of drug pricing - especially in the US - this article leaves out enough relevant information that I would consider it to be intellectually dishonest.
Where did they run the trials? Across how many sites? Do they plan to apply for marketing approval in the US or EU? Are they the manufacturer? Did they beat the cost of setting up the supply chain and manufacturing facilities prior to the phase 2/3 trials?
The answers to those first three questions will have a huge impact on the price tag.
replies(3):